A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients
NCT01305239
·
clinicaltrials.gov ↗
TERMINATED
Status
398
Enrollment
INDUSTRY
Sponsor class
Stopped
See termination reason in detailed description.
Conditions
Breast Cancer
Interventions
DRUG:
Aromasin
Sponsor
Pfizer